Modulation of kinase-inhibitor interactions by auxiliary protein binding: Crystallography studies on Aurora A interactions with VX-680 and with TPX2

Protein Science

Volumn 17, Issue 10, 2008, Pages 1791-1797

  Zhao, Baoguang ^a   Smallwood, Angela ^a   Yang, Jingsong ^a   Koretke, Kristin ^a   Nurse, Kelvin ^a   Calamari, Amy ^a   Kirkpatrick, Robert B ^a   Lai, Zhihong ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Aurora kinase; Cofactor; Crystal structure; SAR; TPX2

Indexed keywords

AURORA A KINASE; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN; PROTEIN TPX2; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; DRUG PROTEIN BINDING; ENZYME INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN STRUCTURE;

CATALYTIC DOMAIN; CELL CYCLE PROTEINS; CRYSTALLOGRAPHY; CRYSTALLOGRAPHY, X-RAY; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; NUCLEAR PROTEINS; PIPERAZINES; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; RECOMBINANT PROTEINS;

EID: 52949141884     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1110/ps.036590.108     Document Type: Article

References (27)

1. Anderson, K., Yang, J., Koretke, K., Nurse, K., Calamari, A., Kirkpatrick, R.B., Patrick, D., Silva, D., Tummino, P.J., Copeland, R.A., et al. 2007. Binding of TPX2 to Aurora A alters substrate and inhibitor interactions. Biochemistry 46: 10287-10295.
2. Andrews, P.D. 2005. Aurora kinases: Shining lights on the therapeutic horizon? Oncogene 24: 5005-5015.
3. Bayliss, R., Sardon, T., Vernos, I., and Conti, E. 2003. Structural basis of Aurora-A activation by TPX2 at the mitotic spindle. Mol. Cell 12: 851-862.
4. Bayliss, R., Sardon, T., Ebert, J., Lindner, D., Vernos, I., and Conti, E. 2004. Determinants for Aurora-A activation and Aurora-B discrimination by TPX2. Cell Cycle 3: 404-407.
5. Bischoff, J.R., Anderson, L., Zhu, Y., Mossie, K., Ng, L., Souza, B., Schryver, B., Flanagan, P., Clairvoyant, F., Ginther, C., et al. 1998. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J. 17: 3052-3065.
6. Bischoff, J.R. and Plowman, G.D. 1999. The Aurora/Ipl1p kinase family: Regulators of chromosome segregation and cytokinesis. Trends Cell Biol. 9: 454-459.
7. Bossemeyer, D. 1995. Protein kinases-structure and function. FEBS Lett. 369: 57-61.
8. Carmena, M. and Earnshaw, W.C. 2003. The cellular geography of aurora kinases. Nat. Rev. Mol. Cell Biol. 4: 842-854.
9. Cheetham, G.M., Knegtel, R.M., Coll, J.T., Renwick, S.B., Swenson, L., Weber, P., Lippke, J.A., and Austen, D.A. 2002. Crystal structure of Aurora-2, an oncogenic serine/threonine kinase. J. Biol. Chem. 277: 42419-42422.
10. Cheetham, G.M., Charlton, P.A., Golec, J.M., and Pollard, J.R. 2007. Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680. Cancer Lett. 251: 323-329.
11. Eyers, P.A. and Maller, J.L. 2004. Regulation of Xenopus Aurora A activation by TPX2. J. Biol. Chem. 279: 9008-9015.
12. Gautschi, O., Mack, P.C., Davies, A.M., Lara Jr., P.N., and Gandara, D.R. 2006. Aurora kinase inhibitors: A new class of targeted drugs in cancer. Clin. Lung Cancer 8: 93-98.
13. Hanks, S.K., Quinn, A.M., and Hunter, T. 1988. The protein kinase family: Conserved features and deduced phylogeny of the catalytic domains. Science 241: 42-52.
14. Harrington, E.A., Bebbington, D., Moore, J., Rasmussen, R.K., Ajose-Adeogun, A.O., Nakayama, T., Graham, J.A., Demur, C., Hercend, T., Diu-Hercend, A., et al. 2004. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat. Med. 10: 262-267.
15. Heron, N.M., Anderson, M., Blowers, D.P., Breed, J., Eden, J.M., Green, S., Hill, G.B., Johnson, T., Jung, F.H., McMiken, H.H., et al. 2006. SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors. Bioorg. Med. Chem. Lett. 16: 1320-1323.
16. Kufer, T.A., Sillje, H.H., Korner, R., Gruss, O.J., Meraldi, P., and Nigg, E.A. 2002. Human TPX2 is required for targeting Aurora-A kinase to the spindle. J. Cell Biol. 158: 617-623.
17. Liao, J.J. 2007. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. J. Med. Chem. 50: 409-424.
18. McCoy, A.J. 2007. Solving structures of protein complexes by molecular replacement with Phaser. Acta Crystallogr. D Biol. Crystallogr. 63: 32-41.
19. Mohammadi, M., McMahon, G., Sun, L., Tang, C., Hirth, P., Yeh, B.K., Hubbard, S.R., and Schlessinger, J. 1997. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 276: 955-960.
20. Mortlock, A., Keen, N.J., Jung, F.H., Heron, N.M., Foote, K.M., Wilkinson, R., and Green, S. 2005. Progress in the development of selective inhibitors of Aurora kinases. Curr. Top. Med. Chem. 5: 199-213.
21. Nagar, B., Bornmann, W.G., Pellicena, P., Schindler, T., Veach, D.R., Miller, W.T., Clarkson, B., and Kuriyan, J. 2002. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62: 4236-4243.
22. Nolen, B., Taylor, S., and Ghosh, G. 2004. Regulation of protein kinases; controlling activity through activation segment conformation. Mol. Cell 15: 661-675.
23. Nowakowski, J., Cronin, C.N., McRee, D.E., Knuth, M.W., Nelson, C.G., Pavletich, N.P., Rogers, J., Sang, B.C., Scheibe, D.N., Swanson, R.V., et al. 2002. Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases from nanovolume crystallography. Structure 10: 1659-1667.
24. Otwinowski, Z. and Minor, W. 1997. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276: 307-326.
25. Schindler, T., Bornmann, W., Pellicena, P., Miller, W.T., Clarkson, B., and Kuriyan, J. 2000. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289: 1938-1942.
26. Tokarski, J.S., Newitt, J.A., Chang, C.Y., Cheng, J.D., Wittekind, M., Kiefer, S.E., Kish, K., Lee, F.Y., Borzillerri, R., Lombardo, L.J., et al. 2006. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. 66: 5790-5797.
27. Young, M.A., Shah, N.P., Chao, L.H., Seeliger, M., Milanov, Z.V., Biggs III., W.H., Treiber, D.K., Patel, H.K., Zarrinkar, P.P., Lockhart, D.J., et al. 2006. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res. 66: 1007-1014.